ATNM Actinium Pharmaceuticals, Inc.

+0.00  (0%)
Previous Close 1.41
Open 1.40
Price To book 4.37
Market Cap 78.69M
Shares 55,807,000
Volume 166,286
Short Ratio 2.60
Av. Daily Volume 556,267

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated September 2016. Interim analysis due mid-2017.
Acute Myeloid Leukemia (AML)
Phase 3 initiated June 2016. Data due 1H 2018.
Hematopoietic Stem Cells Transplantation

Latest News

  1. Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
  2. Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
  3. Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
  4. Anthem Denies Cigna Breakup Fee as Merger Bid Crumbles
  5. Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
  6. Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
  7. Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
  8. Moleculin Leukemia Drug Gets Orphan Drug Status
  9. Actinium Gets Positive CHMP Opinion for AML Drug
  10. Actinium Pharmaceuticals (ATNM) Receives New Patents, Boosts its Portfolio
  11. Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
  12. Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
  13. Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
  14. Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
  15. Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017